Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial

NCT ID: NCT04115644

Last Updated: 2023-12-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-01

Study Completion Date

2017-09-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the functional outcomes of patients with shoulder pathology treated with either ketorolac or corticosteroid injections, in a randomized double-blinded study. Investigators will compare the effectiveness of ketorolac compared to corticosteroid.

Specific Aim 1:

Hypothesis 1: Injection of the shoulder (in the subacromial space) with Ketorolac will be more effective than corticosteroid injection for the treatment of a variety of shoulder pathologies.

The risks associated with this study primarily concern adverse reactions to the study drugs. The drugs used in this study are not narcotics or habit-forming but can have side effects. The patient's physician will screen for any heart, intestinal, or kidney disease or condition that would increase the chance for the patient to have an unwanted side effect.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed study is a three arm, double-blinded, prospective randomized controlled clinical trial with follow-up immediately after the injection and at day 2, and weeks 1, 2, 4, 6, and 12. In this study investigators will compare the effectiveness of ketorolac compared to corticosteroid.

Subjects being seen for a rotator cuff injury will be randomized into one of three treatment groups pertaining to their pathology. The intervention will begin once the subject has consented and answered the Baseline Outcome Shoulder Questionnaire. The Baseline Outcome Questionnaire consists of the Visual Analog Score, American Shoulder and Elbow Score, Single Assessment Numeric Evaluation, Pittsburgh Sleep Quality Index, Short Form-12, and questions pertaining to patient characteristics, injury characteristics, co-morbidities, patient history, medications, and demographics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Full Thickness Rotator Cuff Tear Rotator Cuff Tendinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (control)

will receive an injection of 5 cc 0.25% Marcaine without epinephrine

Group Type PLACEBO_COMPARATOR

Marcaine (placebo)

Intervention Type DRUG

Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine

Group 2 (ketorolac)

will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml

Group Type EXPERIMENTAL

Ketorolac

Intervention Type DRUG

Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml

Marcaine (placebo)

Intervention Type DRUG

Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine

Group 3 (kenalog)

Pt will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone. Group 3 is standard of care

Group Type OTHER

Marcaine (placebo)

Intervention Type DRUG

Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine

Kenalog

Intervention Type DRUG

Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketorolac

Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml

Intervention Type DRUG

Marcaine (placebo)

Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine

Intervention Type DRUG

Kenalog

Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Toradol Bupivacaine Hydrochloride Triamcinolone Acetonide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Rotator Cuff Tendinitis
* Atraumatic Rotator Cuff Tear
* Rotator Cuff Tear Arthropathy
* Subjects who speak English

Exclusion Criteria

* Age: \< 18 years old
* Prior Shoulder Surgery
* Fracture
* Acute Traumatic Rotator Cuff Tear
* Infection
* Uncontrolled Diabetes Mellitus (HbA1c \>8)
* Recent Prior Shoulder Injection in either the Subacromial space
* Workers Compensation
* History of Gastric Ulcers
* Tumor Involving the Shoulder Region
* Prior history of gastrointestinal bleeding, allergic reactions, impaired renal function, seizures or cardiac arrhythmias
* Subject unable to provide informed consent
* Subjects who don't speak English
* Patients who are pregnant or lactating at time of screening or are of child bearing age
* Patients currently receiving an aspirin, NSAID regimen or any other anti-inflammatory agents that could affect inflammation response.
* Patients with any bleeding disorders.
* Patients with severe renal failure.
* Patients likely to have severe problems maintaining follow-up, including patients diagnosed with severe psychiatric conditions, patients who live too far outside the hospital's catchment area, patients who are incarcerated and patients who have unstable housing situations.
* Patients who are allergic to aspirin, ketorolac tromethamine and other NSAIDs
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Michael Khazzam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Khazzam

PROFESSOR -Orthopaedic Surgery

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Khazzam, MD

Role: PRINCIPAL_INVESTIGATOR

UT Southwestern Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

John Hopkins Shoulder & Sports Medicine

Baltimore, Maryland, United States

Site Status

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Adebajo AO, Nash P, Hazleman BL. A prospective double blind dummy placebo controlled study comparing triamcinolone hexacetonide injection with oral diclofenac 50 mg TDS in patients with rotator cuff tendinitis. J Rheumatol. 1990 Sep;17(9):1207-10.

Reference Type BACKGROUND
PMID: 2290163 (View on PubMed)

Alvarez CM, Litchfield R, Jackowski D, Griffin S, Kirkley A. A prospective, double-blind, randomized clinical trial comparing subacromial injection of betamethasone and xylocaine to xylocaine alone in chronic rotator cuff tendinosis. Am J Sports Med. 2005 Feb;33(2):255-62. doi: 10.1177/0363546504267345.

Reference Type BACKGROUND
PMID: 15701612 (View on PubMed)

Choi WD, Cho DH, Hong YH, Noh JH, Lee ZI, Byun SD. Effects of subacromial bursa injection with corticosteroid and hyaluronidase according to dosage. Ann Rehabil Med. 2013 Oct;37(5):668-74. doi: 10.5535/arm.2013.37.5.668. Epub 2013 Oct 29.

Reference Type BACKGROUND
PMID: 24236254 (View on PubMed)

Blair B, Rokito AS, Cuomo F, Jarolem K, Zuckerman JD. Efficacy of injections of corticosteroids for subacromial impingement syndrome. J Bone Joint Surg Am. 1996 Nov;78(11):1685-9. doi: 10.2106/00004623-199611000-00007.

Reference Type BACKGROUND
PMID: 8934482 (View on PubMed)

Min KS, St Pierre P, Ryan PM, Marchant BG, Wilson CJ, Arrington ED. A double-blind randomized controlled trial comparing the effects of subacromial injection with corticosteroid versus NSAID in patients with shoulder impingement syndrome. J Shoulder Elbow Surg. 2013 May;22(5):595-601. doi: 10.1016/j.jse.2012.08.026. Epub 2012 Nov 22.

Reference Type BACKGROUND
PMID: 23177167 (View on PubMed)

Penning LI, de Bie RA, Walenkamp GH. The effectiveness of injections of hyaluronic acid or corticosteroid in patients with subacromial impingement: a three-arm randomised controlled trial. J Bone Joint Surg Br. 2012 Sep;94(9):1246-52. doi: 10.1302/0301-620X.94B9.28750.

Reference Type BACKGROUND
PMID: 22933498 (View on PubMed)

Karthikeyan S, Kwong HT, Upadhyay PK, Parsons N, Drew SJ, Griffin D. A double-blind randomised controlled study comparing subacromial injection of tenoxicam or methylprednisolone in patients with subacromial impingement. J Bone Joint Surg Br. 2010 Jan;92(1):77-82. doi: 10.1302/0301-620X.92B1.22137.

Reference Type BACKGROUND
PMID: 20044683 (View on PubMed)

Koester MC, Dunn WR, Kuhn JE, Spindler KP. The efficacy of subacromial corticosteroid injection in the treatment of rotator cuff disease: A systematic review. J Am Acad Orthop Surg. 2007 Jan;15(1):3-11. doi: 10.5435/00124635-200701000-00002.

Reference Type BACKGROUND
PMID: 17213378 (View on PubMed)

Marder RA, Kim SH, Labson JD, Hunter JC. Injection of the subacromial bursa in patients with rotator cuff syndrome: a prospective, randomized study comparing the effectiveness of different routes. J Bone Joint Surg Am. 2012 Aug 15;94(16):1442-7. doi: 10.2106/JBJS.K.00534.

Reference Type BACKGROUND
PMID: 22992814 (View on PubMed)

Balasubramaniam P, Prathap K. The effect of injection of hydrocortisone into rabbit calcaneal tendons. J Bone Joint Surg Br. 1972 Nov;54(4):729-34. No abstract available.

Reference Type BACKGROUND
PMID: 4639447 (View on PubMed)

Kapetanos G. The effect of the local corticosteroids on the healing and biomechanical properties of the partially injured tendon. Clin Orthop Relat Res. 1982 Mar;(163):170-9.

Reference Type BACKGROUND
PMID: 7067249 (View on PubMed)

Oxlund H. The influence of a local injection of cortisol on the mechanical properties of tendons and ligaments and the indirect effect on skin. Acta Orthop Scand. 1980 Apr;51(2):231-8. doi: 10.3109/17453678008990791.

Reference Type BACKGROUND
PMID: 7435179 (View on PubMed)

Wiggins ME, Fadale PD, Barrach H, Ehrlich MG, Walsh WR. Healing characteristics of a type I collagenous structure treated with corticosteroids. Am J Sports Med. 1994 Mar-Apr;22(2):279-88. doi: 10.1177/036354659402200221.

Reference Type BACKGROUND
PMID: 8198200 (View on PubMed)

Wei AS, Callaci JJ, Juknelis D, Marra G, Tonino P, Freedman KB, Wezeman FH. The effect of corticosteroid on collagen expression in injured rotator cuff tendon. J Bone Joint Surg Am. 2006 Jun;88(6):1331-8. doi: 10.2106/JBJS.E.00806.

Reference Type BACKGROUND
PMID: 16757768 (View on PubMed)

Dogan N, Erdem AF, Gundogdu C, Kursad H, Kizilkaya M. The effects of ketorolac and morphine on articular cartilage and synovium in the rabbit knee joint. Can J Physiol Pharmacol. 2004 Jul;82(7):502-5. doi: 10.1139/y04-066.

Reference Type BACKGROUND
PMID: 15389297 (View on PubMed)

Jean YH, Wen ZH, Chang YC, Hsieh SP, Tang CC, Wang YH, Wong CS. Intra-articular injection of the cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cruciate ligament-transected knee in rats: role of excitatory amino acids. Osteoarthritis Cartilage. 2007 Jun;15(6):638-45. doi: 10.1016/j.joca.2006.11.008. Epub 2007 Jan 2.

Reference Type BACKGROUND
PMID: 17198754 (View on PubMed)

Itzkowitch D, Ginsberg F, Leon M, Bernard V, Appelboom T. Peri-articular injection of tenoxicam for painful shoulders: a double-blind, placebo controlled trial. Clin Rheumatol. 1996 Nov;15(6):604-9. doi: 10.1007/BF02238552.

Reference Type BACKGROUND
PMID: 8973872 (View on PubMed)

Kenaolg Package Insert. July 2014; Available from: http://packageinserts.bms.com/pi/pi_kenalog-40.pdf.

Reference Type BACKGROUND

Ketorolac: Drug Class and Mechanism. 2014; Available from: http://www.medicinenet.com/ketorolac-oral/article.htm

Reference Type BACKGROUND

Ogbru, O. Marcaine - Drug Class and Mechanism. 6/27/2014; Available from: http://www.medicinenet.com/bupivicaine-injection/article.htm.

Reference Type BACKGROUND

Kenalog: Drug Summary. Available from: http://www.pdr.net/drug-summary/kenalog-40?druglabelid=2494

Reference Type BACKGROUND

Hawker, G.A., et al. Measures of Adult Pain. 2011; Available from: http://onlinelibrary.wiley.com/doi/10.1002/acr.20543/pdf

Reference Type BACKGROUND

Gould D, Kelly D, Goldstone L, Gammon J. Examining the validity of pressure ulcer risk assessment scales: developing and using illustrated patient simulations to collect the data. J Clin Nurs. 2001 Sep;10(5):697-706. doi: 10.1046/j.1365-2702.2001.00525.x.

Reference Type BACKGROUND
PMID: 11822520 (View on PubMed)

Michener LA, McClure PW, Sennett BJ. American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form, patient self-report section: reliability, validity, and responsiveness. J Shoulder Elbow Surg. 2002 Nov-Dec;11(6):587-94. doi: 10.1067/mse.2002.127096.

Reference Type BACKGROUND
PMID: 12469084 (View on PubMed)

Richards RR, An KN, Bigliani LU, Friedman RJ, Gartsman GM, Gristina AG, Iannotti JP, Mow VC, Sidles JA, Zuckerman JD. A standardized method for the assessment of shoulder function. J Shoulder Elbow Surg. 1994 Nov;3(6):347-52. doi: 10.1016/S1058-2746(09)80019-0. Epub 2009 Feb 13.

Reference Type BACKGROUND
PMID: 22958838 (View on PubMed)

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

Reference Type BACKGROUND
PMID: 2748771 (View on PubMed)

Gerstenfeld LC, Al-Ghawas M, Alkhiary YM, Cullinane DM, Krall EA, Fitch JL, Webb EG, Thiede MA, Einhorn TA. Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. J Bone Joint Surg Am. 2007 Jan;89(1):114-25. doi: 10.2106/JBJS.F.00495.

Reference Type BACKGROUND
PMID: 17200318 (View on PubMed)

Ho ML, Chang JK, Wang GJ. Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits. Pharmacology. 1998 Sep;57(3):148-59. doi: 10.1159/000028236.

Reference Type BACKGROUND
PMID: 9691235 (View on PubMed)

O'Keefe RJ, Tiyapatanaputi P, Xie C, Li TF, Clark C, Zuscik MJ, Chen D, Drissi H, Schwarz E, Zhang X. COX-2 has a critical role during incorporation of structural bone allografts. Ann N Y Acad Sci. 2006 Apr;1068:532-42. doi: 10.1196/annals.1346.012.

Reference Type BACKGROUND
PMID: 16831949 (View on PubMed)

Haws MJ, Kucan JO, Roth AC, Suchy H, Brown RE. The effects of chronic ketorolac tromethamine (toradol) on wound healing. Ann Plast Surg. 1996 Aug;37(2):147-51. doi: 10.1097/00000637-199608000-00005.

Reference Type BACKGROUND
PMID: 8863973 (View on PubMed)

Prisk V, Huard J. Muscle injuries and repair: the role of prostaglandins and inflammation. Histol Histopathol. 2003 Oct;18(4):1243-56. doi: 10.14670/HH-18.1243.

Reference Type BACKGROUND
PMID: 12973691 (View on PubMed)

Radi ZA, Khan NK. Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing. Inflamm Res. 2005 Sep;54(9):358-66. doi: 10.1007/s00011-005-1367-4.

Reference Type BACKGROUND
PMID: 16273333 (View on PubMed)

Sucato DJ, Lovejoy JF, Agrawal S, Elerson E, Nelson T, McClung A. Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2008 May 1;33(10):1119-24. doi: 10.1097/BRS.0b013e31816f6a2a.

Reference Type BACKGROUND
PMID: 18449047 (View on PubMed)

Pradhan BB, Tatsumi RL, Gallina J, Kuhns CA, Wang JC, Dawson EG. Ketorolac and spinal fusion: does the perioperative use of ketorolac really inhibit spinal fusion? Spine (Phila Pa 1976). 2008 Sep 1;33(19):2079-82. doi: 10.1097/BRS.0b013e31818396f4.

Reference Type BACKGROUND
PMID: 18698276 (View on PubMed)

Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine (Phila Pa 1976). 1998 Apr 1;23(7):834-8. doi: 10.1097/00007632-199804010-00020.

Reference Type BACKGROUND
PMID: 9563116 (View on PubMed)

Park SY, Moon SH, Park MS, Oh KS, Lee HM. The effects of ketorolac injected via patient controlled analgesia postoperatively on spinal fusion. Yonsei Med J. 2005 Apr 30;46(2):245-51. doi: 10.3349/ymj.2005.46.2.245.

Reference Type BACKGROUND
PMID: 15861498 (View on PubMed)

Mullis BH, Copland ST, Weinhold PS, Miclau T, Lester GE, Bos GD. Effect of COX-2 inhibitors and non-steroidal anti-inflammatory drugs on a mouse fracture model. Injury. 2006 Sep;37(9):827-37. doi: 10.1016/j.injury.2005.12.018. Epub 2006 Feb 23.

Reference Type BACKGROUND
PMID: 16497308 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STU 092014-097

Identifier Type: -

Identifier Source: org_study_id